{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:27:47Z","timestamp":1793874467375,"version":"4.6.1"},"reference-count":224,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001249"],"award-info":[{"award-number":["82001249"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971183"],"award-info":[{"award-number":["81971183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171401"],"award-info":[{"award-number":["82171401"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971187"],"award-info":[{"award-number":["81971187"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["20ZR1445400"],"award-info":[{"award-number":["20ZR1445400"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Municipal Science and Technology Major Project","award":["2018SHZDZX05"],"award-info":[{"award-number":["2018SHZDZX05"]}]},{"name":"Shanghai Sailing Program","award":["20YF1440200"],"award-info":[{"award-number":["20YF1440200"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The impact of coronavirus disease 2019 (COVID-19) pandemic on patients with neurodegenerative diseases and the specific neurological manifestations of COVID-19 have aroused great interest. However, there are still many issues of concern to be clarified. Therefore, we review the current literature on the complex relationship between COVID-19 and neurodegenerative diseases with an emphasis on Parkinson\u2019s disease (PD) and Alzheimer\u2019s disease (AD). We summarize the impact of COVID-19 infection on symptom severity, disease progression, and mortality rate of PD and AD, and discuss whether COVID-19 infection could trigger PD and AD. In addition, the susceptibility to and the prognosis of COVID-19 in PD patients and AD patients are also included. In order to achieve better management of PD and AD patients, modifications of care strategies, specific drug therapies, and vaccines during the pandemic are also listed. At last, mechanisms underlying the link of COVID-19 with PD and AD are reviewed.<\/jats:p>","DOI":"10.1186\/s40035-023-00337-1","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T09:04:29Z","timestamp":1675069469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Links between COVID-19 and Parkinson\u2019s disease\/Alzheimer\u2019s disease: reciprocal impacts, medical care strategies and underlying mechanisms"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1593-1516","authenticated-orcid":false,"given":"Pei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Yan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Di","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"337_CR1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/mds.28084","volume":"35","author":"A Lippi","year":"2020","unstructured":"Lippi A, Domingues R, Setz C, Outeiro TF, Krisko A. SARS-CoV-2: at the crossroad between aging and neurodegeneration. Mov Disord. 2020;35:716\u201320.","journal-title":"Mov Disord"},{"key":"337_CR2","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199\u2013207.","journal-title":"N Engl J Med"},{"key":"337_CR3","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3233\/JPD-202249","volume":"10","author":"EG Brown","year":"2020","unstructured":"Brown EG, Chahine LM, Goldman SM, Korell M, Mann E, Kinel DR, et al. The effect of the COVID-19 pandemic on people with Parkinson\u2019s disease. J Parkinsons Dis. 2020;10:1365\u201377.","journal-title":"J Parkinsons Dis"},{"key":"337_CR4","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.3233\/JPD-212779","volume":"11","author":"C Ineichen","year":"2021","unstructured":"Ineichen C, Baumann-Vogel H, Sitzler M, Waldvogel D, Baumann CR. Worsened Parkinson\u2019s disease progression: impact of the COVID-19 pandemic. J Parkinsons Dis. 2021;11:1579\u201383.","journal-title":"J Parkinsons Dis"},{"key":"337_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3233\/JAD-200604","volume":"76","author":"C Boutoleau-Bretonni\u00e8re","year":"2020","unstructured":"Boutoleau-Bretonni\u00e8re C, Pouclet-Courtemanche H, Gillet A, Bernard A, Deruet AL, Gouraud I, et al. The effects of confinement on neuropsychiatric symptoms in Alzheimer\u2019s disease during the COVID-19 crisis. J Alzheimers Dis. 2020;76:41\u20137.","journal-title":"J Alzheimers Dis"},{"key":"337_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.589901","volume":"11","author":"A Barguilla","year":"2020","unstructured":"Barguilla A, Fern\u00e1ndez-Lebrero A, Estragu\u00e9s-G\u00e1zquez I, Garc\u00eda-Escobar G, Navalpotro-G\u00f3mez I, Manero RM, et al. Effects of COVID-19 pandemic confinement in patients with cognitive impairment. Front Neurol. 2020;11:589901.","journal-title":"Front Neurol"},{"key":"337_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.711658","volume":"12","author":"ZC Chen","year":"2021","unstructured":"Chen ZC, Liu S, Gan J, Ma L, Du X, Zhu H, et al. The impact of the COVID-19 pandemic and lockdown on mild cognitive impairment, Alzheimer\u2019s disease and dementia with lewy bodies in China: a 1-year follow-up study. Front Psychiatr. 2021;12:711658.","journal-title":"Front Psychiatr"},{"key":"337_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.nrl.2020.03.001","volume":"35","author":"J Mat\u00edas-Guiu","year":"2020","unstructured":"Mat\u00edas-Guiu J, Gomez-Pinedo U, Montero-Escribano P, Gomez-Iglesias P, Porta-Etessam J, Matias-Guiu JA. Should we expect neurological symptoms in the SARS-CoV-2 epidemic? Neurologia (Engl Ed). 2020;35:170\u20135.","journal-title":"Neurologia (Engl Ed)"},{"key":"337_CR9","doi-asserted-by":"publisher","first-page":"R373","DOI":"10.1152\/ajpregu.00292.2006","volume":"292","author":"MF Doobay","year":"2007","unstructured":"Doobay MF, Talman LS, Obr TD, Tian X, Davisson RL, Lazartigues E. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol. 2007;292:R373\u201381.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"337_CR10","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.bbi.2019.12.011","volume":"87","author":"AI Rodriguez-Perez","year":"2020","unstructured":"Rodriguez-Perez AI, Garrido-Gil P, Pedrosa MA, Garcia-Garrote M, Valenzuela R, Navarro G, et al. Angiotensin type 2 receptors: role in aging and neuroinflammation in the substantia nigra. Brain Behav Immun. 2020;87:256\u201371.","journal-title":"Brain Behav Immun"},{"key":"337_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.parkreldis.2022.04.011","volume":"98","author":"U Fedeli","year":"2022","unstructured":"Fedeli U, Casotto V, Barbiellini Amidei C, Saia M, Tiozzo SN, Basso C, et al. Parkinson\u2019s disease related mortality: long-term trends and impact of COVID-19 pandemic waves. Parkinsonism Relat Disord. 2022;98:75\u20137.","journal-title":"Parkinsonism Relat Disord"},{"key":"337_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15505","author":"C Zenesini","year":"2022","unstructured":"Zenesini C, Vignatelli L, Belotti LMB, Baccari F, Calandra-Buonaura G, Cortelli P, et al. Risk of SARS-CoV-2 infection, hospitalization and death for COVID-19 in people with Parkinson\u2019s disease or parkinsonism over a 15-month period: a cohort study. Eur J Neurol. 2022;10.1111\/ene.15505.\u00a0","journal-title":"Eur J Neurol"},{"key":"337_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40035-021-00237-2","volume":"10","author":"X Xia","year":"2021","unstructured":"Xia X, Wang Y, Zheng J. COVID-19 and Alzheimer\u2019s disease: how one crisis worsens the other. Transl Neurodegener. 2021;10:15.","journal-title":"Transl Neurodegener"},{"key":"337_CR14","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1093\/gerona\/glaa183","volume":"75","author":"JL Atkins","year":"2020","unstructured":"Atkins JL, Masoli JAH, Delgado J, Pilling LC, Kuo CL, Kuchel GA, et al. Preexisting comorbidities predicting COVID-19 and mortality in the UK biobank community cohort. J Gerontol A Biol Sci Med Sci. 2020;75:2224\u201330.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"337_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S1474-4422(20)30221-0","volume":"19","author":"MA Ellul","year":"2020","unstructured":"Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767\u201383.","journal-title":"Lancet Neurol"},{"key":"337_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41582-020-0386-7","volume":"16","author":"H Wood","year":"2020","unstructured":"Wood H. New insights into the neurological effects of COVID-19. Nat Rev Neurol. 2020;16:403.","journal-title":"Nat Rev Neurol"},{"key":"337_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/NRL.0b013e318251e6f2","volume":"18","author":"KS Zheng","year":"2012","unstructured":"Zheng KS, Dorfman BJ, Christos PJ, Khadem NR, Henchcliffe C, Piboolnurak P, et al. Clinical characteristics of exacerbations in Parkinson disease. Neurologist. 2012;18:120\u20134.","journal-title":"Neurologist"},{"key":"337_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094944","volume":"9","author":"A Umemura","year":"2014","unstructured":"Umemura A, Oeda T, Tomita S, Hayashi R, Kohsaka M, Park K, et al. Delirium and high fever are associated with subacute motor deterioration in Parkinson disease: a nested case-control study. PLoS ONE. 2014;9:e94944.","journal-title":"PLoS ONE"},{"key":"337_CR19","doi-asserted-by":"publisher","first-page":"15014","DOI":"10.1038\/npjparkd.2015.14","volume":"1","author":"F Brugger","year":"2015","unstructured":"Brugger F, Erro R, Balint B, K\u00e4gi G, Barone P, Bhatia KP. Why is there motor deterioration in Parkinson\u2019s disease during systemic infections-a hypothetical view. NPJ Parkinsons Dis. 2015;1:15014.","journal-title":"NPJ Parkinsons Dis"},{"key":"337_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3233\/JPD-202038","volume":"10","author":"RC Helmich","year":"2020","unstructured":"Helmich RC, Bloem BR. The impact of the COVID-19 pandemic on Parkinson\u2019s disease: hidden sorrows and emerging opportunities. J Parkinsons Dis. 2020;10:351\u20134.","journal-title":"J Parkinsons Dis"},{"key":"337_CR21","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3233\/JPD-202251","volume":"10","author":"A Van Der Heide","year":"2020","unstructured":"Van Der Heide A, Meinders MJ, Bloem BR, Helmich RC. The impact of the COVID-19 pandemic on psychological distress, physical activity, and symptom severity in Parkinson\u2019s disease. J Parkinsons Dis. 2020;10:1355\u201364.","journal-title":"J Parkinsons Dis"},{"key":"337_CR22","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00415-020-10002-6","volume":"268","author":"E Del Prete","year":"2021","unstructured":"Del Prete E, Francesconi A, Palermo G, Mazzucchi S, Frosini D, Morganti R, et al. Prevalence and impact of COVID-19 in Parkinson\u2019s disease: evidence from a multi-center survey in Tuscany region. J Neurol. 2021;268:1179\u201387.","journal-title":"J Neurol"},{"key":"337_CR23","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/mds.28261","volume":"35","author":"D Santos-Garc\u00eda","year":"2020","unstructured":"Santos-Garc\u00eda D, Oreiro M, P\u00e9rez P, Fanjul G, Paz Gonz\u00e1lez JM, Feal Painceiras MJ, et al. Impact of coronavirus disease 2019 pandemic on Parkinson\u2019s disease: a cross-sectional survey of 568 Spanish patients. Mov Disord. 2020;35:1712\u20136.","journal-title":"Mov Disord"},{"key":"337_CR24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/mdc3.13231","volume":"8","author":"R Parihar","year":"2021","unstructured":"Parihar R, Ferastraoaru V, Galanopoulou AS, Geyer HL, Kaufman DM. Outcome of hospitalized Parkinson\u2019s disease patients with and without COVID-19. Mov Disord Clin Pract. 2021;8:859\u201367.","journal-title":"Mov Disord Clin Pract"},{"key":"337_CR25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.parkreldis.2020.08.012","volume":"78","author":"A Fasano","year":"2020","unstructured":"Fasano A, Elia AE, Dallocchio C, Canesi M, Alimonti D, Sorbera C, et al. Predictors of COVID-19 outcome in Parkinson\u2019s disease. Park Relat Disord. 2020;78:134\u20137.","journal-title":"Park Relat Disord"},{"key":"337_CR26","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/mds.28176","volume":"35","author":"A Fasano","year":"2020","unstructured":"Fasano A, Cereda E, Barichella M, Cassani E, Ferri V, Zecchinelli AL, et al. COVID-19 in Parkinson\u2019s disease patients living in Lombardy, Italy. Mov Disord. 2020;35:1089\u201393.","journal-title":"Mov Disord"},{"key":"337_CR27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s13365-018-0707-4","volume":"25","author":"L Meng","year":"2019","unstructured":"Meng L, Shen L, Ji HF. Impact of infection on risk of Parkinson\u2019s disease: a quantitative assessment of case-control and cohort studies. J Neurovirol. 2019;25:221\u20138.","journal-title":"J Neurovirol"},{"key":"337_CR28","doi-asserted-by":"publisher","first-page":"e2109","DOI":"10.1212\/WNL.0000000000010282","volume":"95","author":"A M\u00e9ndez-Guerrero","year":"2020","unstructured":"M\u00e9ndez-Guerrero A, Laespada-Garc\u00eda MI, G\u00f3mez-Grande A, Ruiz-Ortiz M, Blanco-Palmero VA, Azcarate-Diaz FJ, et al. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Neurology. 2020;95:e2109\u201318.","journal-title":"Neurology"},{"key":"337_CR29","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S1474-4422(20)30305-7","volume":"19","author":"ME Cohen","year":"2020","unstructured":"Cohen ME, Eichel R, Steiner-Birmanns B, Janah A, Ioshpa M, Bar-Shalom R, et al. A case of probable Parkinson\u2019s disease after SARS-CoV-2 infection. Lancet Neurol. 2020;19:804\u20135.","journal-title":"Lancet Neurol"},{"key":"337_CR30","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3389\/fneur.2020.01044","volume":"11","author":"P Chan\u00e1-Cuevas","year":"2020","unstructured":"Chan\u00e1-Cuevas P, Salles-G\u00e1ndara P, Rojas-Fernandez A, Salinas-Rebolledo C, Mil\u00e1n-Sol\u00e9 A. The potential role of SARS-COV-2 in the pathogenesis of Parkinson\u2019s disease. Front Neurol. 2020;11:1044.","journal-title":"Front Neurol"},{"issue":"12","key":"337_CR31","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.3390\/brainsci11121654","volume":"11","author":"L Krey","year":"2021","unstructured":"Krey L, Huber MK, H\u00f6glinger GU, Wegner F. Can SARS-CoV-2 infection lead to neurodegeneration and Parkinson\u2019s disease? Brain Sci. 2021;11:1654.","journal-title":"Brain Sci"},{"key":"337_CR32","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.1073\/pnas.1906466117","volume":"117","author":"R Marreiros","year":"2020","unstructured":"Marreiros R, M\u00fcller-Schiffmann A, Trossbach SV, Prikulis I, H\u00e4nsch S, Weidtkamp-Peters S, et al. Disruption of cellular proteostasis by H1N1 influenza A virus causes \u03b1-synuclein aggregation. Proc Natl Acad Sci U S A. 2020;117:6741\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"337_CR33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/bs.pmbts.2019.06.002","volume":"168","author":"CT Tulisiak","year":"2019","unstructured":"Tulisiak CT, Mercado G, Peelaerts W, Brundin L, Brundin P. Can infections trigger alpha-synucleinopathies? Prog Mol Biol Transl Sci. 2019;168:299\u2013322.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"337_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41593-020-00758-5","volume":"24","author":"J Meinhardt","year":"2021","unstructured":"Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021;24:168\u201375.","journal-title":"Nat Neurosci"},{"issue":"5","key":"337_CR35","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3390\/brainsci12050536","volume":"12","author":"JM Morowitz","year":"2022","unstructured":"Morowitz JM, Pogson KB, Roque DA, Church FC. Role of SARS-CoV-2 in modifying neurodegenerative processes in Parkinson\u2019s disease: a narrative review. Brain Sci. 2022;12:536.","journal-title":"Brain Sci"},{"issue":"5","key":"337_CR36","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/v13050897","volume":"13","author":"E Estrada","year":"2021","unstructured":"Estrada E. Cascading from SARS-CoV-2 to Parkinson\u2019s disease through protein-protein interactions. Viruses. 2021;13:897.","journal-title":"Viruses"},{"key":"337_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S1474-4422(20)30442-7","volume":"20","author":"M Merello","year":"2021","unstructured":"Merello M, Bhatia KP, Obeso JA. SARS-CoV-2 and the risk of Parkinson\u2019s disease: facts and fantasy. Lancet Neurol. 2021;20:94\u20135.","journal-title":"Lancet Neurol"},{"key":"337_CR38","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.tins.2020.10.009","volume":"43","author":"P Brundin","year":"2020","unstructured":"Brundin P, Nath A, Beckham JD. Is COVID-19 a perfect storm for Parkinson\u2019s disease? Trends Neurosci. 2020;43:931\u20133.","journal-title":"Trends Neurosci"},{"key":"337_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/aje\/kwm260","volume":"167","author":"H Chen","year":"2008","unstructured":"Chen H, O\u2019reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson\u2019s disease. Am J Epidemiol. 2008;167:90\u20135.","journal-title":"Am J Epidemiol"},{"key":"337_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101111","volume":"40","author":"L Liu","year":"2021","unstructured":"Liu L, Ni SY, Yan W, Lu QD, Zhao YM, Xu YY, et al. Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality: a systematic review, meta-analysis and call for action. EClinicalMedicine. 2021;40:101111.","journal-title":"EClinicalMedicine"},{"key":"337_CR41","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/mds.28104","volume":"35","author":"A Antonini","year":"2020","unstructured":"Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson\u2019s disease patients affected by COVID-19. Mov Disord. 2020;35:905\u20138.","journal-title":"Mov Disord"},{"key":"337_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102163","volume":"42","author":"K Rejdak","year":"2020","unstructured":"Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord. 2020;42:102163.","journal-title":"Mult Scler Relat Disord"},{"key":"337_CR43","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/mdc3.12952","volume":"7","author":"AJ Stoessl","year":"2020","unstructured":"Stoessl AJ, Bhatia KP, Merello M. Movement disorders in the world of COVID-19. Mov Disord Clin Pract. 2020;7:355\u20136.","journal-title":"Mov Disord Clin Pract"},{"key":"337_CR44","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/mds.28586","volume":"36","author":"R Scherbaum","year":"2021","unstructured":"Scherbaum R, Kwon EH, Richter D, Bartig D, Gold R, Krogias C, et al. Clinical profiles and mortality of COVID-19 inpatients with Parkinson\u2019s disease in Germany. Mov Disord. 2021;36:1049\u201357.","journal-title":"Mov Disord"},{"key":"337_CR45","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.parkreldis.2021.04.019","volume":"87","author":"C Putri","year":"2021","unstructured":"Putri C, Hariyanto TI, Hananto JE, Christian K, Situmeang RFV, Kurniawan A. Parkinson\u2019s disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: a systematic review, meta-analysis, and meta-regression. Park Relat Disord. 2021;87:155\u201361.","journal-title":"Park Relat Disord"},{"key":"337_CR46","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3233\/JAD-210319","volume":"84","author":"JJS Rutten","year":"2021","unstructured":"Rutten JJS, Van Kooten J, Van Loon AM, Van Buul LW, Joling KJ, Smalbrugge M, et al. Dementia and Parkinson\u2019s disease: risk factors for 30-day mortality in nursing home residents with COVID-19. J Alzheimers Dis. 2021;84:1173\u201381.","journal-title":"J Alzheimers Dis"},{"key":"337_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mds.28408","volume":"36","author":"L Vignatelli","year":"2021","unstructured":"Vignatelli L, Zenesini C, Belotti LMB, Baldin E, Bonavina G, Calandra-Buonaura G, et al. Risk of hospitalization and death for COVID-19 in people with Parkinson\u2019s disease or Parkinsonism. Mov Disord. 2021;36:1\u201310.","journal-title":"Mov Disord"},{"key":"337_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2278","volume":"32","author":"AE El-Qushayri","year":"2022","unstructured":"El-Qushayri AE, Ghozy S, Reda A, Kamel AMA, Abbas AS, Dmytriw AA. The impact of Parkinson\u2019s disease on manifestations and outcomes of Covid-19 patients: a systematic review and meta-analysis. Rev Med Virol. 2022;32:e2278.","journal-title":"Rev Med Virol"},{"key":"337_CR49","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.parkreldis.2020.05.021","volume":"75","author":"AK Srivastav","year":"2020","unstructured":"Srivastav AK, Samuel AJ. E-rehabilitation: one solution for patients with Parkinson\u2019s disease in COVID-19 era. Park Relat Disord. 2020;75:128\u20139.","journal-title":"Park Relat Disord"},{"key":"337_CR50","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3233\/JPD-202108","volume":"10","author":"E Cubo","year":"2020","unstructured":"Cubo E, Hassan A, Bloem BR, Mari Z. Implementation of telemedicine for urgent and ongoing healthcare for patients with Parkinson\u2019s disease during the COVID-19 pandemic: new expectations for the future. J Parkinsons Dis. 2020;10:911\u20133.","journal-title":"J Parkinsons Dis"},{"key":"337_CR51","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3390\/healthcare10061065","volume":"10","author":"F Ruggiero","year":"2022","unstructured":"Ruggiero F, Lombi L, Molisso MT, Fiore G, Zirone E, Ferrucci R, et al. The impact of telemedicine on Parkinson\u2019s care during the COVID-19 pandemic: an Italian online survey. Healthcare (Basel). 2022;10:1065.","journal-title":"Healthcare (Basel)"},{"key":"337_CR52","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.parkreldis.2021.08.018","volume":"91","author":"JA De Rus","year":"2021","unstructured":"De Rus JA, Bogard S, Normandeau CP, Degroot C, Postuma RB, Dupr\u00e9 N, et al. Clinical perception and management of Parkinson\u2019s disease during the COVID-19 pandemic: a Canadian experience. Park Relat Disord. 2021;91:66\u201376.","journal-title":"Park Relat Disord"},{"key":"337_CR53","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1177\/15459683211046254","volume":"35","author":"ME Morris","year":"2021","unstructured":"Morris ME, Slade SC, Wittwer JE, Blackberry I, Haines S, Hackney ME, et al. Online dance therapy for people with Parkinson\u2019s disease: feasibility and impact on consumer engagement. Neurorehabil Neural Repair. 2021;35:1076\u201387.","journal-title":"Neurorehabil Neural Repair"},{"key":"337_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.678124","volume":"12","author":"J Bek","year":"2021","unstructured":"Bek J, Groves M, Leventhal D, Poliakoff E. Dance at home for people with Parkinson\u2019s during COVID-19 and beyond: participation, perceptions, and prospects. Front Neurol. 2021;12:678124.","journal-title":"Front Neurol"},{"key":"337_CR55","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00415-020-10273-z","volume":"268","author":"J Xu","year":"2021","unstructured":"Xu J, Wang J, Keith S, Zhang M, Yang C, Yuan Q, et al. Management of Parkinson\u2019s disease patients after DBS by remote programming: preliminary application of single center during quarantine of 2019-nCoV. J Neurol. 2021;268:1295\u2013303.","journal-title":"J Neurol"},{"key":"337_CR56","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.arcmed.2020.06.009","volume":"51","author":"R Ara\u00fajo","year":"2020","unstructured":"Ara\u00fajo R, Aranda-Mart\u00ednez JD, Aranda-Abreu GE. Amantadine treatment for people with COVID-19. Arch Med Res. 2020;51:739\u201340.","journal-title":"Arch Med Res"},{"key":"337_CR57","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/jmv.26179","volume":"93","author":"GE Aranda-Abreu","year":"2021","unstructured":"Aranda-Abreu GE, Aranda-Mart\u00ednez JD, Ara\u00fajo R. Use of amantadine in a patient with SARS-CoV-2. J Med Virol. 2021;93:110\u20131.","journal-title":"J Med Virol"},{"key":"337_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.704186","volume":"12","author":"WA Kamel","year":"2021","unstructured":"Kamel WA, Kamel MI, Alhasawi A, Elmasry S, Alhamdan F, Al-Hashel JY. Effect of pre-exposure use of amantadine on COVID-19 infection: a hospital-based cohort study in patients with Parkinson\u2019s disease or multiple sclerosis. Front Neurol. 2021;12:704186.","journal-title":"Front Neurol"},{"key":"337_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106004","volume":"55","author":"SP Smieszek","year":"2020","unstructured":"Smieszek SP, Przychodzen BP, Polymeropoulos MH. Amantadine disrupts lysosomal gene expression: a hypothesis for COVID19 treatment. Int J Antimicrob Agents. 2020;55:106004.","journal-title":"Int J Antimicrob Agents"},{"key":"337_CR60","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1002\/jmv.25826","volume":"92","author":"S Nataf","year":"2020","unstructured":"Nataf S. An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19. J Med Virol. 2020;92:1743\u20134.","journal-title":"J Med Virol"},{"key":"337_CR61","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1007\/s00415-020-10272-0","volume":"268","author":"R Sainz-Amo","year":"2021","unstructured":"Sainz-Amo R, Baena-lvarez B, Pare\u00e9s I, S\u00e1nchez-D\u00edez G, P\u00e9rez-Torre P, L\u00f3pez-Send\u00f3n JL, et al. COVID-19 in Parkinson\u2019s disease: What holds the key? J Neurol. 2021;268:2666\u201370.","journal-title":"J Neurol"},{"key":"337_CR62","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"DE Gordon","year":"2020","unstructured":"Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459\u201368.","journal-title":"Nature"},{"key":"337_CR63","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1192\/bjp.2020.151","volume":"219","author":"R Govind","year":"2021","unstructured":"Govind R, Fonseca De Freitas D, Pritchard M, Hayes RD, Maccabe JH. Clozapine treatment and risk of COVID-19 infection: retrospective cohort study. Br J Psychiatr. 2021;219:368\u201374.","journal-title":"Br J Psychiatr"},{"key":"337_CR64","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1111\/ene.14912","volume":"28","author":"D Chambergo-Michilot","year":"2021","unstructured":"Chambergo-Michilot D, Barros-Sevillano S, Rivera-Torrej\u00f3n O, De La Cruz-Ku GA, Custodio N. Factors associated with COVID-19 in people with Parkinson\u2019s disease: a systematic review and meta-analysis. Eur J Neurol. 2021;28:3467\u201377.","journal-title":"Eur J Neurol"},{"key":"337_CR65","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.bbrc.2021.10.042","volume":"583","author":"T Behl","year":"2021","unstructured":"Behl T, Kumar S, Sehgal A, Singh S, Sharma N, Chirgurupati S, et al. Linking COVID-19 and Parkinson\u2019s disease: targeting the role of vitamin-D. Biochem Biophys Res Commun. 2021;583:14\u201321.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"337_CR66","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3390\/brainsci10050284","volume":"10","author":"CA Hribar","year":"2020","unstructured":"Hribar CA, Cobbold PH, Church FC. Potential role of vitamin D in the elderly to resist COVID-19 and to slow progression of Parkinson\u2019s Disease. Brain Sci. 2020;10:284.","journal-title":"Brain Sci"},{"key":"337_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.inat.2021.101441","volume":"27","author":"AY Azzam","year":"2022","unstructured":"Azzam AY, Ghozy S, Azab MA. Vitamin D and its\u2019 role in Parkinson\u2019s disease patients with SARS-CoV-2 infection. A review article. Interdiscip Neurosurg. 2022;27:101441.","journal-title":"Interdiscip Neurosurg"},{"key":"337_CR68","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/joim.13149","volume":"289","author":"JM Rhodes","year":"2021","unstructured":"Rhodes JM, Subramanian S, Laird E, Griffin G, Kenny RA. Perspective: vitamin D deficiency and COVID-19 severity\u2013plausibly linked by latitude, ethnicity, impacts on cytokines, ACE2 and thrombosis. J Intern Med. 2021;289:97\u2013115.","journal-title":"J Intern Med"},{"key":"337_CR69","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3233\/JPD-212573","volume":"11","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Trenkwalder C, Sanchez-Ferro A, Kalia LV, Alcalay R, Chiang HL, et al. COVID-19 vaccination for persons with Parkinson\u2019s disease: Light at the end of the tunnel? J Parkinsons Dis. 2021;11:3\u20138.","journal-title":"J Parkinsons Dis"},{"key":"337_CR70","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1002\/mds.28772","volume":"36","author":"R Erro","year":"2021","unstructured":"Erro R, Buonomo AR, Barone P, Pellecchia MT. Severe dyskinesia after administration of SARS-CoV2 mRNA vaccine in Parkinson\u2019s disease. Mov Disord. 2021;36:2219.","journal-title":"Mov Disord"},{"key":"337_CR71","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1007\/s10072-022-06182-w","volume":"43","author":"G Imbalzano","year":"2022","unstructured":"Imbalzano G, Ledda C, Artusi CA, Romagnolo A, Montanaro E, Rizzone MG, et al. SARS-CoV-2 vaccination, Parkinson\u2019s disease, and other movement disorders: case series and short literature review. Neurol Sci. 2022;43:5165-8.","journal-title":"Neurol Sci"},{"key":"337_CR72","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s10072-021-05753-7","volume":"43","author":"E Contaldi","year":"2022","unstructured":"Contaldi E, Comi C, Cantello R, Magistrelli L. Motor and non-motor symptom improvement after mRNA-1273 vaccine in a Parkinson\u2019s disease patient. Neurol Sci. 2022;43:1447\u20138.","journal-title":"Neurol Sci"},{"key":"337_CR73","doi-asserted-by":"publisher","first-page":"827","DOI":"10.5114\/aoms\/134716","volume":"17","author":"JJ Fedorowski","year":"2021","unstructured":"Fedorowski JJ. Could amantadine interfere with COVID-19 vaccines based on the LNP-mRNA platform? Arch Med Sci. 2021;17:827\u20138.","journal-title":"Arch Med Sci"},{"key":"337_CR74","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/jcp.22112","volume":"224","author":"J Kornhuber","year":"2010","unstructured":"Kornhuber J, Henkel AW, Groemer TW, St\u00e4dtler S, Welzel O, Tripal P, et al. Lipophilic cationic drugs increase the permeability of lysosomal membranes in a cell culture system. J Cell Physiol. 2010;224:152\u201364.","journal-title":"J Cell Physiol"},{"key":"337_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101615","volume":"36","author":"E Gkogkou","year":"2020","unstructured":"Gkogkou E, Barnasas G, Vougas K, Trougakos IP. Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators. Redox Biol. 2020;36:101615.","journal-title":"Redox Biol"},{"issue":"2","key":"337_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271\u201380.e8.","journal-title":"Cell"},{"key":"337_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.573095","volume":"11","author":"R Chen","year":"2020","unstructured":"Chen R, Wang K, Yu J, Howard D, French L, Chen Z, et al. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains. Front Neurol. 2020;11:573095.","journal-title":"Front Neurol"},{"issue":"5","key":"337_CR78","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3390\/biomedicines10051000","volume":"10","author":"A Anghelescu","year":"2022","unstructured":"Anghelescu A, Onose G, Popescu C, B\u0103il\u0103 M, Stoica SI, Postoiu R, et al. Parkinson\u2019s disease and SARS-CoV-2 infection: particularities of molecular and cellular mechanisms regarding pathogenesis and treatment. Biomedicines. 2022;10:1000.","journal-title":"Biomedicines"},{"key":"337_CR79","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1002\/mds.28680","volume":"36","author":"R Bouali-Benazzouz","year":"2021","unstructured":"Bouali-Benazzouz R, Benazzouz A. Covid-19 infection and Parkinsonism: Is there a link? Mov Disord. 2021;36:1737\u201343.","journal-title":"Mov Disord"},{"key":"337_CR80","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41380-020-00965-3","volume":"26","author":"DE Ribeiro","year":"2021","unstructured":"Ribeiro DE, Oliveira-Giacomelli A, Glaser T, Arnaud-Sampaio VF, Andrejew R, Dieckmann L, et al. Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology. Mol Psychiatr. 2021;26:1044\u201359.","journal-title":"Mol Psychiatr"},{"issue":"13","key":"337_CR81","doi-asserted-by":"publisher","first-page":"7135","DOI":"10.3390\/ijms22137135","volume":"22","author":"C Conte","year":"2021","unstructured":"Conte C. Possible link between SARS-CoV-2 infection and Parkinson\u2019s disease: the role of toll-like receptor 4. Int J Mol Sci. 2021;22:7135.","journal-title":"Int J Mol Sci"},{"key":"337_CR82","doi-asserted-by":"publisher","first-page":"184","DOI":"10.14802\/jmd.21046","volume":"14","author":"S Sinha","year":"2021","unstructured":"Sinha S, Mittal S, Roy R. Parkinson\u2019s disease and the COVID-19 pandemic: A review article on the association between SARS-CoV-2 and \u03b1-synucleinopathy. J Mov Disord. 2021;14:184\u201392.","journal-title":"J Mov Disord"},{"key":"337_CR83","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1007\/s12035-020-02236-2","volume":"58","author":"M Dolatshahi","year":"2021","unstructured":"Dolatshahi M, Sabahi M, Aarabi MH. Pathophysiological clues to how the emergent SARS-CoV-2 can potentially increase the susceptibility to neurodegeneration. Mol Neurobiol. 2021;58:2379\u201394.","journal-title":"Mol Neurobiol"},{"key":"337_CR84","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1111\/ene.15045","volume":"28","author":"G Cosentino","year":"2021","unstructured":"Cosentino G, Todisco M, Hota N, Della Porta G, Morbini P, Tassorelli C, et al. Neuropathological findings from COVID-19 patients with neurological symptoms argue against a direct brain invasion of SARS-CoV-2: a critical systematic review. Eur J Neurol. 2021;28:3856\u201365.","journal-title":"Eur J Neurol"},{"key":"337_CR85","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41577-020-0305-6","volume":"20","author":"N Vaninov","year":"2020","unstructured":"Vaninov N. In the eye of the COVID-19 cytokine storm. Nat Rev Immunol. 2020;20:277.","journal-title":"Nat Rev Immunol"},{"key":"337_CR86","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1474-4422(20)30308-2","volume":"19","author":"J Matschke","year":"2020","unstructured":"Matschke J, L\u00fctgehetmann M, Hagel C, Sperhake JP, Schr\u00f6der AS, Edler C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19:919\u201329.","journal-title":"Lancet Neurol"},{"key":"337_CR87","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41418-018-0124-5","volume":"26","author":"E Lee","year":"2019","unstructured":"Lee E, Hwang I, Park S, Hong S, Hwang B, Cho Y, et al. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ. 2019;26:213\u201328.","journal-title":"Cell Death Differ"},{"key":"337_CR88","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.freeradbiomed.2015.06.021","volume":"88","author":"LE Tebay","year":"2015","unstructured":"Tebay LE, Robertson H, Durant ST, Vitale SR, Penning TM, Dinkova-Kostova AT, et al. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic Biol Med. 2015;88:108\u201346.","journal-title":"Free Radic Biol Med"},{"key":"337_CR89","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.12688\/f1000research.12111.1","volume":"6","author":"T Satoh","year":"2017","unstructured":"Satoh T, Lipton S. Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate. F1000Res. 2017;6:2138.","journal-title":"F1000Res"},{"issue":"1","key":"337_CR90","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/antiox11010124","volume":"11","author":"T Satoh","year":"2022","unstructured":"Satoh T, Trudler D, Oh CK, Lipton SA. Potential therapeutic use of the rosemary diterpene carnosic acid for Alzheimer\u2019s disease, Parkinson\u2019s disease, and long-COVID through NRF2 activation to counteract the NLRP3 inflammasome. Antioxidants (Basel). 2022;11:124.","journal-title":"Antioxidants (Basel)"},{"key":"337_CR91","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fnana.2015.00091","volume":"9","author":"J Blesa","year":"2015","unstructured":"Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR. Oxidative stress and Parkinson\u2019s disease. Front Neuroanat. 2015;9:91.","journal-title":"Front Neuroanat"},{"key":"337_CR92","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/JPD-130230","volume":"3","author":"V Dias","year":"2013","unstructured":"Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson\u2019s disease. J Parkinsons Dis. 2013;3:461\u201391.","journal-title":"J Parkinsons Dis"},{"key":"337_CR93","doi-asserted-by":"publisher","first-page":"C258","DOI":"10.1152\/ajpcell.00224.2020","volume":"319","author":"KK Singh","year":"2020","unstructured":"Singh KK, Chaubey G, Chen JY, Suravajhala P. Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis. Am J Physiol Cell Physiol. 2020;319:C258\u201367.","journal-title":"Am J Physiol Cell Physiol"},{"key":"337_CR94","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.bbrc.2017.11.055","volume":"495","author":"TT Shi","year":"2018","unstructured":"Shi TT, Yang FY, Liu C, Cao X, Lu J, Zhang XL, et al. Angiotensin-converting enzyme 2 regulates mitochondrial function in pancreatic \u03b2-cells. Biochem Biophys Res Commun. 2018;495:860\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"337_CR95","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.freeradbiomed.2014.07.033","volume":"76","author":"EA Bordt","year":"2014","unstructured":"Bordt EA, Polster BM. NADPH oxidase- and mitochondria-derived reactive oxygen species in proinflammatory microglial activation: A bipartisan affair? Free Radic Biol Med. 2014;76:34\u201346.","journal-title":"Free Radic Biol Med"},{"key":"337_CR96","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3389\/fnins.2019.00916","volume":"13","author":"K Morimoto","year":"2019","unstructured":"Morimoto K, Nakajima K. Role of the immune system in the development of the central nervous system. Front Neurosci. 2019;13:916.","journal-title":"Front Neurosci"},{"key":"337_CR97","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00401-021-02268-5","volume":"141","author":"AS Harms","year":"2021","unstructured":"Harms AS, Ferreira SA, Romero-Ramos M. Periphery and brain, innate and adaptive immunity in Parkinson\u2019s disease. Acta Neuropathol. 2021;141:527\u201345.","journal-title":"Acta Neuropathol"},{"key":"337_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.572090","volume":"12","author":"K Mayne","year":"2020","unstructured":"Mayne K, White JA, Mcmurran CE, Rivera FJ, De La Fuente AG. Aging and neurodegenerative disease: Is the adaptive immune system a friend or foe? Front Aging Neurosci. 2020;12:572090.","journal-title":"Front Aging Neurosci"},{"key":"337_CR99","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.bbi.2020.10.007","volume":"91","author":"L Li","year":"2021","unstructured":"Li L, Acioglu C, Heary RF, Elkabes S. Role of astroglial toll-like receptors (TLRs) in central nervous system infections, injury and neurodegenerative diseases. Brain Behav Immun. 2021;91:740\u201355.","journal-title":"Brain Behav Immun"},{"key":"337_CR100","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.neurol.2017.12.003","volume":"174","author":"A Alexoudi","year":"2018","unstructured":"Alexoudi A, Alexoudi I, Gatzonis S. Parkinson\u2019s disease pathogenesis, evolution and alternative pathways: a review. Rev Neurol (Paris). 2018;174:699\u2013704.","journal-title":"Rev Neurol (Paris)"},{"key":"337_CR101","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1021\/acschemneuro.1c00666","volume":"13","author":"SA Semerdzhiev","year":"2022","unstructured":"Semerdzhiev SA, Fakhree MA, Segers-Nolten I, Blum C, Claessens M. Interactions between SARS-CoV-2 N-Protein and \u03b1-synuclein accelerate amyloid formation. ACS Chem Neurosci. 2022;13:143\u201350.","journal-title":"ACS Chem Neurosci"},{"key":"337_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.719807","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Xia Y, Yin S, Wan F, Hu J, Kou L, et al. Targeting microglial \u03b1-synuclein\/TLRs\/NF-kappaB\/NLRP3 inflammasome axis in Parkinson\u2019s disease. Front Immunol. 2021;12:719807.","journal-title":"Front Immunol"},{"issue":"7","key":"337_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.053","volume":"184","author":"X Ren","year":"2021","unstructured":"Ren X, Wen W, Fan X, Hou W, Su B, Cai P, et al. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell. 2021;184:1895\u2013913.e19.","journal-title":"Cell"},{"key":"337_CR104","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/brain\/awab009","volume":"144","author":"JA Hosp","year":"2021","unstructured":"Hosp JA, Dressing A, Blazhenets G, Bormann T, Rau A, Schwabenland M, et al. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain. 2021;144:1263\u201376.","journal-title":"Brain"},{"key":"337_CR105","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1093\/brain\/awab148","volume":"144","author":"KT Thakur","year":"2021","unstructured":"Thakur KT, Miller EH, Glendinning MD, Al-Dalahmah O, Banu MA, Boehme AK, et al. COVID-19 neuropathology at Columbia University Irving Medical Center\/New York Presbyterian Hospital. Brain. 2021;144:2696\u2013708.","journal-title":"Brain"},{"key":"337_CR106","doi-asserted-by":"publisher","first-page":"e20202135","DOI":"10.1084\/jem.20202135","volume":"218","author":"E Song","year":"2021","unstructured":"Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. 2021;218:e20202135.","journal-title":"J Exp Med."},{"key":"337_CR107","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/WAD.0000000000000485","volume":"36","author":"AT Yu","year":"2022","unstructured":"Yu AT, Absar NM. Long-term Neuropsychiatric Complications and 18F-FDG-PET Hypometabolism in the brain from prolonged infection of COVID-19. Alzheimer Dis Assoc Disord. 2022;36:173\u20135.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"337_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2019.112366","volume":"379","author":"JL Peterman","year":"2020","unstructured":"Peterman JL, White JD, Calcagno A, Hagen C, Quiring M, Paulhus K, et al. Prolonged isolation stress accelerates the onset of Alzheimer\u2019s disease-related pathology in 5xFAD mice despite running wheels and environmental enrichment. Behav Brain Res. 2020;379:112366.","journal-title":"Behav Brain Res"},{"key":"337_CR109","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1007\/s00213-014-3629-8","volume":"231","author":"H Dong","year":"2014","unstructured":"Dong H, Wang S, Zeng Z, Li F, Montalvo-Ortiz J, Tucker C, et al. Effects of corticotrophin-releasing factor receptor 1 antagonists on amyloid-\u03b2 and behavior in Tg2576 mice. Psychopharmacology. 2014;231:4711\u201322.","journal-title":"Psychopharmacology"},{"key":"337_CR110","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/npp.2011.69","volume":"36","author":"YH Hsiao","year":"2011","unstructured":"Hsiao YH, Chen PS, Chen SH, Gean PW. The involvement of Cdk5 activator p35 in social isolation-triggered onset of early Alzheimer\u2019s disease-related cognitive deficit in the transgenic mice. Neuropsychopharmacology. 2011;36:1848\u201358.","journal-title":"Neuropsychopharmacology"},{"key":"337_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.625781","volume":"12","author":"I Rainero","year":"2020","unstructured":"Rainero I, Bruni AC, Marra C, Cagnin A, Bonanni L, Cupidi C, et al. The impact of COVID-19 quarantine on patients with dementia and family caregivers: a nation-wide survey. Front Aging Neurosci. 2020;12:625781.","journal-title":"Front Aging Neurosci"},{"key":"337_CR112","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1093\/brain\/awaa240","volume":"143","author":"RW Paterson","year":"2020","unstructured":"Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020;143:3104\u201320.","journal-title":"Brain"},{"key":"337_CR113","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s12603-020-1389-1","volume":"24","author":"A Bianchetti","year":"2020","unstructured":"Bianchetti A, Rozzini R, Guerini F, Boffelli S, Ranieri P, Minelli G, et al. Clinical presentation of COVID19 in dementia patients. J Nutr Health Aging. 2020;24:560\u20132.","journal-title":"J Nutr Health Aging"},{"key":"337_CR114","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3389\/fpsyt.2020.00866","volume":"11","author":"G Cohen","year":"2020","unstructured":"Cohen G, Russo MJ, Campos JA, Allegri RF. COVID-19 epidemic in Argentina: worsening of behavioral symptoms in elderly subjects with dementia living in the community. Front Psychiatr. 2020;11:866.","journal-title":"Front Psychiatr"},{"key":"337_CR115","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3233\/JAD-220118","volume":"88","author":"A Tsiakiri","year":"2022","unstructured":"Tsiakiri A, Vlotinou P, Terzoudi A, Heliopoulos I, Vadikolias K. Cognitive, functional, and emotional changes during the COVID-19 pandemic in Greek patients with neurocognitive disorders. J Alzheimers Dis. 2022;88:537\u201347.","journal-title":"J Alzheimers Dis"},{"key":"337_CR116","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1038\/s41598-022-05687-w","volume":"12","author":"G Wei","year":"2022","unstructured":"Wei G, Diehl-Schmid J, Matias-Guiu JA, Pijnenburg Y, Landin-Romero R, Bogaardt H, et al. The effects of the COVID-19 pandemic on neuropsychiatric symptoms in dementia and carer mental health: an international multicentre study. Sci Rep. 2022;12:2418.","journal-title":"Sci Rep"},{"key":"337_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.572583","volume":"11","author":"A Muntsant","year":"2020","unstructured":"Muntsant A, Gim\u00e9nez-Llort L. Impact of social isolation on the behavioral, functional profiles, and hippocampal atrophy asymmetry in dementia in times of coronavirus pandemic (COVID-19): a translational neuroscience approach. Front Psychiatr. 2020;11:572583.","journal-title":"Front Psychiatr"},{"key":"337_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.703481","volume":"12","author":"J Gan","year":"2021","unstructured":"Gan J, Liu S, Wu H, Chen Z, Fei M, Xu J, et al. The impact of the COVID-19 pandemic on Alzheimer\u2019s disease and other dementias. Front Psychiatr. 2021;12:703481.","journal-title":"Front Psychiatr"},{"key":"337_CR119","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1007\/s00415-021-10848-4","volume":"269","author":"E Beghi","year":"2022","unstructured":"Beghi E, Giussani G, Westenberg E, Allegri R, Garcia-Azorin D, Guekht A, et al. Acute and post-acute neurological manifestations of COVID-19: present findings, critical appraisal, and future directions. J Neurol. 2022;269:2265\u201374.","journal-title":"J Neurol"},{"key":"337_CR120","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41591-021-01292-y","volume":"27","author":"CH Sudre","year":"2021","unstructured":"Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626\u201331.","journal-title":"Nat Med"},{"key":"337_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101019","volume":"38","author":"HE Davis","year":"2021","unstructured":"Davis HE, Assaf GS, Mccorkell L, Wei H, Low RJ, Re\u2019em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.","journal-title":"EClinicalMedicine"},{"key":"337_CR122","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1001\/jama.2022.18931","volume":"328","author":"S Wulf Hanson","year":"2022","unstructured":"Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604\u201315.","journal-title":"JAMA"},{"key":"337_CR123","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-021-03710-0","volume":"595","author":"AC Yang","year":"2021","unstructured":"Yang AC, Kern F, Losada PM, Agam MR, Maat CA, Schmartz GP, et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature. 2021;595:565\u201371.","journal-title":"Nature"},{"key":"337_CR124","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1038\/s41467-022-30932-1","volume":"13","author":"M Charnley","year":"2022","unstructured":"Charnley M, Islam S, Bindra GK, Engwirda J, Ratcliffe J, Zhou J, et al. Neurotoxic amyloidogenic peptides in the proteome of SARS-COV2: potential implications for neurological symptoms in COVID-19. Nat Commun. 2022;13:3387.","journal-title":"Nat Commun"},{"key":"337_CR125","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/alz.12558","volume":"18","author":"S Reiken","year":"2022","unstructured":"Reiken S, Sittenfeld L, Dridi H, Liu Y, Liu X, Marks AR. Alzheimer\u2019s-like signaling in brains of COVID-19 patients. Alzheimers Dement. 2022;18:955\u201365.","journal-title":"Alzheimers Dement"},{"key":"337_CR126","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/alz.12556","volume":"18","author":"JA Frontera","year":"2022","unstructured":"Frontera JA, Boutajangout A, Masurkar AV, Betensky RA, Ge Y, Vedvyas A, et al. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer\u2019s dementia. Alzheimers Dement. 2022;18:899\u2013910.","journal-title":"Alzheimers Dement"},{"key":"337_CR127","doi-asserted-by":"publisher","first-page":"866153","DOI":"10.3389\/fimmu.2022.866153","volume":"13","author":"M Guasp","year":"2022","unstructured":"Guasp M, Mu\u00f1oz-S\u00e1nchez G, Mart\u00ednez-Hern\u00e1ndez E, Santana D, Carbayo A, Naranjo L, et al. CSF Biomarkers in COVID-19 associated encephalopathy and encephalitis predict long-term outcome. Front Immunol. 2022;13:866153.","journal-title":"Front Immunol"},{"key":"337_CR128","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1007\/s00259-020-05178-y","volume":"48","author":"A Kas","year":"2021","unstructured":"Kas A, Soret M, Pyatigoskaya N, Habert MO, Hesters A, Le Guennec L, et al. The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur J Nucl Med Mol Imaging. 2021;48:2543\u201357.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"337_CR129","doi-asserted-by":"publisher","first-page":"910","DOI":"10.2967\/jnumed.121.262128","volume":"62","author":"G Blazhenets","year":"2021","unstructured":"Blazhenets G, Schroeter N, Bormann T, Thurow J, Wagner D, Frings L, et al. Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. J Nucl Med. 2021;62:910\u20135.","journal-title":"J Nucl Med"},{"key":"337_CR130","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41586-022-04569-5","volume":"604","author":"G Douaud","year":"2022","unstructured":"Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, Mccarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604:697\u2013707.","journal-title":"Nature"},{"key":"337_CR131","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/s41591-022-02001-z","volume":"28","author":"E Xu","year":"2022","unstructured":"Xu E, Xie Y, Al-Aly Z. Long-term neurologic outcomes of COVID-19. Nat Med. 2022;28:2406\u201315.","journal-title":"Nat Med"},{"key":"337_CR132","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-022-04442-5","volume":"603","author":"H Shuai","year":"2022","unstructured":"Shuai H, Chan JF, Hu B, Chai Y, Yuen TT, Yin F, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature. 2022;603:693\u20139.","journal-title":"Nature"},{"key":"337_CR133","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-022-04856-1","volume":"607","author":"R Uraki","year":"2022","unstructured":"Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature. 2022;607:119\u201327.","journal-title":"Nature"},{"key":"337_CR134","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41586-022-04474-x","volume":"603","author":"B Meng","year":"2022","unstructured":"Meng B, Abdullahi A, Ferreira I, Goonawardane N, Saito A, Kimura I, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706\u201314.","journal-title":"Nature"},{"key":"337_CR135","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41586-022-05482-7","volume":"612","author":"R Uraki","year":"2022","unstructured":"Uraki R, Halfmann PJ, Iida S, Yamayoshi S, Furusawa Y, Kiso M, et al. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. Nature. 2022;612:540\u20135.","journal-title":"Nature"},{"key":"337_CR136","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/S0140-6736(22)00327-0","volume":"399","author":"C Menni","year":"2022","unstructured":"Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022;399:1618\u201324","journal-title":"Lancet"},{"key":"337_CR137","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/YCO.0000000000000806","volume":"35","author":"N Pai","year":"2022","unstructured":"Pai N, Vella SL. The physical and mental health consequences of social isolation and loneliness in the context of COVID-19. Curr Opin Psychiatr. 2022;35:305\u201310.","journal-title":"Curr Opin Psychiatr"},{"issue":"2","key":"337_CR138","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1212\/WNL.0000000000200583","volume":"99","author":"C Shen","year":"2022","unstructured":"Shen C, Rolls E, Cheng W, Kang J, Dong G, Xie C, et al. Associations of social isolation and loneliness with later dementia. Neurology. 2022;99:e164\u201375.","journal-title":"Neurology"},{"key":"337_CR139","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1002\/alz.12296","volume":"17","author":"Q Wang","year":"2021","unstructured":"Wang Q, Davis PB, Gurney ME, Xu R. COVID-19 and dementia: analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimers Dement. 2021;17:1297\u2013306.","journal-title":"Alzheimers Dement"},{"key":"337_CR140","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/alz.12665","volume":"18","author":"Y Wang","year":"2022","unstructured":"Wang Y, Li M, Kazis LE, Xia W. Clinical outcomes of COVID-19 infection among patients with Alzheimer\u2019s disease or mild cognitive impairment. Alzheimers Dement. 2022;18:911\u201323.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"337_CR141","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/geriatrics6010010","volume":"6","author":"Y Yu","year":"2021","unstructured":"Yu Y, Travaglio M, Popovic R, Leal NS, Martins LM. Alzheimer\u2019s and Parkinson\u2019s diseases predict different COVID-19 outcomes: a UK Biobank Study. Geriatrics (Basel). 2021;6:10.","journal-title":"Geriatrics (Basel)"},{"key":"337_CR142","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3233\/JAD-220031","volume":"87","author":"SJ Chung","year":"2022","unstructured":"Chung SJ, Chang Y, Jeon J, Shin JI, Song TJ, Kim J. Association of Alzheimer\u2019s disease with COVID-19 susceptibility and severe complications: a nationwide cohort study. J Alzheimers Dis. 2022;87:701\u201310.","journal-title":"J Alzheimers Dis"},{"key":"337_CR143","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/alz.12143","volume":"16","author":"VCT Mok","year":"2020","unstructured":"Mok VCT, Pendlebury S, Wong A, Alladi S, Au L, Bath PM, et al. Tackling challenges in care of Alzheimer\u2019s disease and other dementias amid the COVID-19 pandemic, now and in the future. Alzheimers Dement. 2020;16:1571\u201381.","journal-title":"Alzheimers Dement"},{"key":"337_CR144","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/ggi.13960","volume":"20","author":"M Covino","year":"2020","unstructured":"Covino M, De Matteis G, Santoro M, Sabia L, Simeoni B, Candelli M, et al. Clinical characteristics and prognostic factors in COVID-19 patients aged \u226580 years. Geriatr Gerontol Int. 2020;20:704\u20138.","journal-title":"Geriatr Gerontol Int"},{"key":"337_CR145","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.3233\/JAD-201016","volume":"78","author":"N Liu","year":"2020","unstructured":"Liu N, Sun J, Wang X, Zhao M, Huang Q, Li H. The impact of dementia on the clinical outcome of COVID-19: a systematic review and meta-analysis. J Alzheimers Dis. 2020;78:1775\u201382.","journal-title":"J Alzheimers Dis"},{"key":"337_CR146","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/ggi.14107","volume":"21","author":"J July","year":"2021","unstructured":"July J, Pranata R. Prevalence of dementia and its impact on mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis. Geriatr Gerontol Int. 2021;21:172\u20137.","journal-title":"Geriatr Gerontol Int"},{"key":"337_CR147","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1093\/gerona\/glaa131","volume":"75","author":"CL Kuo","year":"2020","unstructured":"Kuo CL, Pilling LC, Atkins JL, Masoli JH, Delgado J, Kuchel GA, et al. APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort. J Gerontol A Biol Sci Med Sci. 2020;75:2231\u20132.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"337_CR148","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41586-022-05344-2","volume":"611","author":"BN Ostendorf","year":"2022","unstructured":"Ostendorf BN, Patel MA, Bilanovic J, Hoffmann HH, Carrasco SE, Rice CM, et al. Common human genetic variants of APOE impact murine COVID-19 mortality. Nature. 2022;611:346\u201351.","journal-title":"Nature"},{"key":"337_CR149","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s40478-021-01302-7","volume":"9","author":"SN Kurki","year":"2021","unstructured":"Kurki SN, Kantonen J, Kaivola K, Hokkanen L, M\u00e4yr\u00e4np\u00e4\u00e4 MI, Puttonen H, et al. APOE \u03b54 associates with increased risk of severe COVID-19, cerebral microhaemorrhages and post-COVID mental fatigue: a Finnish biobank, autopsy and clinical study. Acta Neuropathol Commun. 2021;9:199.","journal-title":"Acta Neuropathol Commun"},{"key":"337_CR150","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-020-03065-y","volume":"591","author":"E Pairo-Castineira","year":"2021","unstructured":"Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic mechanisms of critical illness in COVID-19. Nature. 2021;591:92\u20138.","journal-title":"Nature"},{"key":"337_CR151","doi-asserted-by":"publisher","first-page":"fcz022","DOI":"10.1093\/braincomms\/fcz022","volume":"1","author":"DA Salih","year":"2019","unstructured":"Salih DA, Bayram S, Guelfi S, Reynolds RH, Shoai M, Ryten M, et al. Genetic variability in response to amyloid beta deposition influences Alzheimer\u2019s disease risk. Brain Commun. 2019;1:fcz022.","journal-title":"Brain Commun"},{"key":"337_CR152","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1212\/WNL.0000000000008708","volume":"94","author":"JM Hatcher-Martin","year":"2020","unstructured":"Hatcher-Martin JM, Adams JL, Anderson ER, Bove R, Burrus TM, Chehrenama M, et al. Telemedicine in neurology: telemedicine work group of the American Academy of Neurology update. Neurology. 2020;94:30\u20138.","journal-title":"Neurology"},{"key":"337_CR153","volume":"12","author":"MR Geddes","year":"2020","unstructured":"Geddes MR, O\u2019connell ME, Fisk JD, Gauthier S, Camicioli R, Ismail Z. Remote cognitive and behavioral assessment: report of the Alzheimer Society of Canada task force on dementia care best practices for COVID-19. Alzheimers Dement (Amst). 2020;12:e12111.","journal-title":"Alzheimers Dement (Amst)"},{"key":"337_CR154","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/1357633X15615049","volume":"23","author":"H Kim","year":"2017","unstructured":"Kim H, Jhoo JH, Jang JW. The effect of telemedicine on cognitive decline in patients with dementia. J Telemed Telecare. 2017;23:149\u201354.","journal-title":"J Telemed Telecare"},{"key":"337_CR155","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1001\/jamainternmed.2019.4101","volume":"179","author":"KL Possin","year":"2019","unstructured":"Possin KL, Merrilees JJ, Dulaney S, Bonasera SJ, Chiong W, Lee K, et al. Effect of collaborative dementia care via telephone and internet on quality of life, caregiver well-being, and health care use: the care ecosystem randomized clinical trial. JAMA Intern Med. 2019;179:1658\u201367.","journal-title":"JAMA Intern Med"},{"key":"337_CR156","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10072-019-04105-w","volume":"41","author":"JH Park","year":"2020","unstructured":"Park JH, Kim BS, Ovbiagele B. Concomitant diabetes or hypertension with metabolic syndrome on the extent of intracranial atherosclerotic stenosis. Neurol Sci. 2020;41:387\u201395.","journal-title":"Neurol Sci"},{"key":"337_CR157","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3233\/JAD-215459","volume":"86","author":"A Morin","year":"2022","unstructured":"Morin A, Pressat-Laffouilhere T, Sarazin M, Lagarde J, Roue-Jagot C, Olivieri P, et al. Telemedicine in French Memory Clinics during the COVID-19 pandemic. J Alzheimers Dis. 2022;86:525\u201330.","journal-title":"J Alzheimers Dis"},{"key":"337_CR158","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.577629","volume":"11","author":"WB Soares","year":"2020","unstructured":"Soares WB, Silvestre IT, Lima AMO, De Almondes KM. The influence of telemedicine care on the management of behavioral and psychological symptoms in dementia (BPSD) risk factors induced or exacerbated during the COVID-19 pandemic. Front Psychiatr. 2020;11:577629.","journal-title":"Front Psychiatr"},{"key":"337_CR159","doi-asserted-by":"publisher","DOI":"10.2196\/19434","volume":"22","author":"JM Goodman-Casanova","year":"2020","unstructured":"Goodman-Casanova JM, Dura-Perez E, Guzman-Parra J, Cuesta-Vargas A, Mayoral-Cleries F. Telehealth home support during COVID-19 confinement for community-dwelling older adults with mild cognitive impairment or mild dementia: survey study. J Med Internet Res. 2020;22:e19434.","journal-title":"J Med Internet Res"},{"key":"337_CR160","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.jagp.2020.07.019","volume":"28","author":"FH Lai","year":"2020","unstructured":"Lai FH, Yan EW, Yu KK, Tsui WS, Chan DT, Yee BK. The protective impact of telemedicine on persons with dementia and their caregivers during the COVID-19 pandemic. Am J Geriatr Psychiatr. 2020;28:1175\u201384.","journal-title":"Am J Geriatr Psychiatr"},{"issue":"Suppl 8","key":"337_CR161","volume":"17","author":"M Noroozian","year":"2021","unstructured":"Noroozian M, Mohammadian F. Lessons from COVID-19 pandemic: clinical experiences on telemedicine in patients with dementia in Iran. Alzheimers Dement. 2021;17(Suppl 8):e057468.","journal-title":"Alzheimers Dement"},{"key":"337_CR162","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.761965","volume":"12","author":"S Elbaz","year":"2021","unstructured":"Elbaz S, Cinalioglu K, Sekhon K, Gruber J, Rigas C, Bodenstein K, et al. A systematic review of telemedicine for older adults with dementia during COVID-19: an alternative to in-person health services? Front Neurol. 2021;12:761965.","journal-title":"Front Neurol"},{"key":"337_CR163","doi-asserted-by":"publisher","first-page":"E371","DOI":"10.1503\/cmaj.201938","volume":"193","author":"PJ Gosse","year":"2021","unstructured":"Gosse PJ, Kassardjian CD, Masellis M, Mitchell SB. Virtual care for patients with Alzheimer disease and related dementias during the COVID-19 era and beyond. CMAJ. 2021;193:E371\u20137.","journal-title":"CMAJ"},{"key":"337_CR164","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jamda.2021.12.033","volume":"23","author":"L Shaughnessy","year":"2022","unstructured":"Shaughnessy L, Brunton S, Chepke C, Farmer JG, Rosenzweig AS, Grossberg G. Using telemedicine to assess and manage psychosis in neurodegenerative diseases in long-term care. J Am Med Dir Assoc. 2022;23:1145\u201352.","journal-title":"J Am Med Dir Assoc"},{"key":"337_CR165","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jagp.2022.01.013","volume":"30","author":"JA Nkodo","year":"2022","unstructured":"Nkodo JA, Gana W, Debacq C, Aidoud A, Poupin P, Camus V, et al. The role of telemedicine in the management of the behavioral and psychological symptoms of dementia: a systematic review. Am J Geriatr Psychiatr. 2022;30:1135\u201350.","journal-title":"Am J Geriatr Psychiatr"},{"key":"337_CR166","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1111\/ene.14320","volume":"27","author":"L Leocani","year":"2020","unstructured":"Leocani L, Diserens K, Moccia M, Caltagirone C. Disability through COVID-19 pandemic: neurorehabilitation cannot wait. Eur J Neurol. 2020;27:e50\u20131.","journal-title":"Eur J Neurol"},{"key":"337_CR167","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.623933","volume":"11","author":"S Bernini","year":"2020","unstructured":"Bernini S, Stasolla F, Panzarasa S, Quaglini S, Sinforiani E, Sandrini G, et al. Cognitive telerehabilitation for older adults with neurodegenerative diseases in the COVID-19 era: a perspective study. Front Neurol. 2020;11: 623933.","journal-title":"Front Neurol"},{"key":"337_CR168","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1186\/s12877-022-03239-5","volume":"22","author":"C Di Lorito","year":"2022","unstructured":"Di Lorito C, Van Der Wardt V, O\u2019brien R, Gladman J, Masud T, Harwood RH. Impact of COVID-19 lockdown on physical exercise among participants receiving the promoting activity, independence and stability in early dementia (PrAISED) intervention: a repeated measure study. BMC Geriatr. 2022;22:605.","journal-title":"BMC Geriatr"},{"key":"337_CR169","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1111\/jgs.17163","volume":"69","author":"AV Kalicki","year":"2021","unstructured":"Kalicki AV, Moody KA, Franzosa E, Gliatto PM, Ornstein KA. Barriers to telehealth access among homebound older adults. J Am Geriatr Soc. 2021;69:2404\u201311.","journal-title":"J Am Geriatr Soc"},{"key":"337_CR170","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1001\/jamainternmed.2020.1661","volume":"180","author":"MA Steinman","year":"2020","unstructured":"Steinman MA, Perry L, Perissinotto CM. Meeting the care needs of older adults isolated at home during the COVID-19 pandemic. JAMA Intern Med. 2020;180:819\u201320.","journal-title":"JAMA Intern Med"},{"key":"337_CR171","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.toxrep.2020.04.012","volume":"7","author":"K Farsalinos","year":"2020","unstructured":"Farsalinos K, Niaura R, Le Houezec J, Barbouni A, Tsatsakis A, Kouretas D, et al. Editorial: nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicol Rep. 2020;7:658\u201363.","journal-title":"Toxicol Rep"},{"key":"337_CR172","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.05.002","volume":"179","author":"DB Hoover","year":"2017","unstructured":"Hoover DB. Cholinergic modulation of the immune system presents new approaches for treating inflammation. Pharmacol Ther. 2017;179:1\u201316.","journal-title":"Pharmacol Ther"},{"key":"337_CR173","first-page":"73","volume":"16","author":"TJ Oscanoa","year":"2021","unstructured":"Oscanoa TJ, Amado J, Vidal X, Romero-Ortuno R. Angiotensin-receptor blockers and the risk of Alzheimer\u00b4s disease: a meta-analysis. Curr Rev Clin Exp Pharmacol. 2021;16:73\u20138.","journal-title":"Curr Rev Clin Exp Pharmacol"},{"key":"337_CR174","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jocn.2016.02.036","volume":"33","author":"S Zhuang","year":"2016","unstructured":"Zhuang S, Wang HF, Wang X, Li J, Xing CM. The association of renin-angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer\u2019s disease: a meta-analysis. J Clin Neurosci. 2016;33:32\u20138.","journal-title":"J Clin Neurosci"},{"key":"337_CR175","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s12079-020-00579-y","volume":"14","author":"VP Jayaseelan","year":"2020","unstructured":"Jayaseelan VP, Paramasivam A. Repurposing calcium channel blockers as antiviral drugs. J Cell Commun Signal. 2020;14:467\u20138.","journal-title":"J Cell Commun Signal"},{"key":"337_CR176","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1021\/acschemneuro.0c00391","volume":"11","author":"CC Danta","year":"2020","unstructured":"Danta CC. Calcium channel blockers: a possible potential therapeutic strategy for the treatment of Alzheimer\u2019s dementia patients with SARS-CoV-2 infection. ACS Chem Neurosci. 2020;11:2145\u20138.","journal-title":"ACS Chem Neurosci"},{"key":"337_CR177","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.29058","volume":"3","author":"N Rosenthal","year":"2020","unstructured":"Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19. JAMA Netw Open. 2020;3:e2029058.","journal-title":"JAMA Netw Open"},{"key":"337_CR178","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","volume":"382","author":"HR Reynolds","year":"2020","unstructured":"Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382:2441\u20138.","journal-title":"N Engl J Med"},{"key":"337_CR179","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/S2589-7500(20)30289-2","volume":"3","author":"DR Morales","year":"2021","unstructured":"Morales DR, Conover MM, You SC, Pratt N, Kostka K, Duarte-Salles T, et al. Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. Lancet Digit Health. 2021;3:e98\u2013114.","journal-title":"Lancet Digit Health"},{"key":"337_CR180","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/jch.14101","volume":"23","author":"AZ Bauer","year":"2021","unstructured":"Bauer AZ, Gore R, Sama SR, Rosiello R, Garber L, Sundaresan D, et al. Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study. J Clin Hypertens (Greenwich). 2021;23:21\u20137.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"337_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2021.102210","volume":"15","author":"MY Alsagaff","year":"2021","unstructured":"Alsagaff MY, Mulia EPB, Maghfirah I, Luke K, Nugraha D, Rachmi DA, et al. Association of calcium channel blocker use with clinical outcome of COVID-19: a meta-analysis. Diabetes Metab Syndr. 2021;15:102210.","journal-title":"Diabetes Metab Syndr"},{"key":"337_CR182","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.chest.2021.01.073","volume":"160","author":"SR Mendez","year":"2021","unstructured":"Mendez SR, Frank RC, Stevenson EK, Chung M, Silverman MG. Dihydropyridine calcium channel blockers and the risk of severe COVID-19. Chest. 2021;160:89\u201393.","journal-title":"Chest"},{"key":"337_CR183","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12669","author":"L Wang","year":"2022","unstructured":"Wang L, Davis PB, Kaelber DC, Xu R. COVID-19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021. Alzheimers Dement. 2022. https:\/\/doi.org\/10.1002\/alz.12669.","journal-title":"Alzheimers Dement."},{"key":"337_CR184","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/psyg.12747","volume":"21","author":"MI Naharci","year":"2021","unstructured":"Naharci MI, Tasci I. Delirium in a patient with Alzheimer\u2019s dementia following COVID-19 vaccination. Psychogeriatrics. 2021;21:846\u20137.","journal-title":"Psychogeriatrics"},{"key":"337_CR185","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1007\/s42399-021-01058-0","volume":"3","author":"R Laudicella","year":"2021","unstructured":"Laudicella R, Burger IA, Panasiti F, Longo C, Scalisi S, Minutoli F, et al. Subcutaneous uptake on [18F]Florbetaben PET\/CT: a case report of possible amyloid-beta immune-reactivity after COVID-19 vaccination. SN Compr Clin Med. 2021;3:2626\u20138.","journal-title":"SN Compr Clin Med"},{"key":"337_CR186","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1931","volume":"374","author":"J Hippisley-Cox","year":"2021","unstructured":"Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, Khunti K, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ. 2021;374: n1931.","journal-title":"BMJ"},{"key":"337_CR187","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","volume":"385","author":"S Pavord","year":"2021","unstructured":"Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021;385:1680\u20139.","journal-title":"N Engl J Med"},{"key":"337_CR188","doi-asserted-by":"publisher","first-page":"e2136","DOI":"10.1212\/WNL.0000000000012896","volume":"97","author":"L Palaiodimou","year":"2021","unstructured":"Palaiodimou L, Stefanou MI, Katsanos AH, Aguiar De Sousa D, Coutinho JM, Lagiou P, et al. Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: a systematic review and meta-analysis. Neurology. 2021;97:e2136\u201347.","journal-title":"Neurology"},{"key":"337_CR189","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1001\/jamaneurol.2021.3619","volume":"78","author":"M S\u00e1nchez Van Kammen","year":"2021","unstructured":"S\u00e1nchez Van Kammen M, Aguiar De Sousa D, Poli S, Cordonnier C, Heldner MR, Van De Munckhof A, et al. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. JAMA Neurol. 2021;78:1314\u201323.","journal-title":"JAMA Neurol"},{"key":"337_CR190","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79:13\u201321.","journal-title":"JAMA Neurol"},{"key":"337_CR191","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9:95.","journal-title":"Alzheimers Res Ther"},{"key":"337_CR192","doi-asserted-by":"publisher","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","volume":"90","author":"JL Cummings","year":"2018","unstructured":"Cummings JL, Cohen S, Van Dyck CH, Brody M, Curtis C, Cho W, et al. ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90:e1889\u201397.","journal-title":"Neurology"},{"key":"337_CR193","first-page":"106","volume":"87","author":"HM Arrighi","year":"2016","unstructured":"Arrighi HM, Barakos J, Barkhof F, Tampieri D, Jack C Jr, Melan\u00e7on D, et al. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer\u2019s disease treated with bapineuzumab: a historical, prospective secondary analysis. J Neurol Neurosurg Psychiatr. 2016;87:106\u201312.","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"337_CR194","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 2021;13:80.","journal-title":"Alzheimers Res Ther"},{"key":"337_CR195","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384:1691\u2013704.","journal-title":"N Engl J Med"},{"key":"337_CR196","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"16","author":"SM Greenberg","year":"2020","unstructured":"Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, Van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease\u2014one peptide, two pathways. Nat Rev Neurol. 2020;16:30\u201342.","journal-title":"Nat Rev Neurol"},{"key":"337_CR197","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/14737175.2022.2053112","volume":"22","author":"A Mohanasundaram","year":"2022","unstructured":"Mohanasundaram A, Thukani Sathanantham S, Sveikata L, Lalla RS, Sveikatien\u0117 R, Kaushik A, et al. Aducanumab and adenoviral COVID-19 vaccines: Increased cerebral hemorrhage risk? Expert Rev Neurother. 2022;22:283\u20136.","journal-title":"Expert Rev Neurother"},{"key":"337_CR198","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40035-022-00316-y","volume":"11","author":"F Chen","year":"2022","unstructured":"Chen F, Chen Y, Wang Y, Ke Q, Cui L. The COVID-19 pandemic and Alzheimer\u2019s disease: mutual risks and mechanisms. Transl Neurodegener. 2022;11:40.","journal-title":"Transl Neurodegener"},{"key":"337_CR199","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12974-021-02339-0","volume":"19","author":"S Jarius","year":"2022","unstructured":"Jarius S, Pache F, K\u00f6rtvelyessy P, Jel\u010di\u0107 I, Stettner M, Franciotta D, et al. Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. J Neuroinflammation. 2022;19:19.","journal-title":"J Neuroinflammation"},{"key":"337_CR200","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.570251","volume":"11","author":"A L\u00f3pez-Reyes","year":"2020","unstructured":"L\u00f3pez-Reyes A, Martinez-Armenta C, Espinosa-Vel\u00e1zquez R, V\u00e1zquez-C\u00e1rdenas P, Cruz-Ramos M, Palacios-Gonzalez B, et al. NLRP3 inflammasome: the stormy link between obesity and COVID-19. Front Immunol. 2020;11:570251.","journal-title":"Front Immunol"},{"key":"337_CR201","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2217\/nmt-2022-0013","volume":"12","author":"H Hampel","year":"2022","unstructured":"Hampel H, Elhage A, Cummings J, Blennow K, Gao P, Jack CR Jr, et al. The AT(N) system for describing biological changes in Alzheimer\u2019s disease: a plain language summary. Neurodegener Dis Manag. 2022;12:231\u20139.","journal-title":"Neurodegener Dis Manag"},{"key":"337_CR202","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41582-021-00549-x","volume":"17","author":"BM Bettcher","year":"2021","unstructured":"Bettcher BM, Tansey MG, Doroth\u00e9e G, Heneka MT. Peripheral and central immune system crosstalk in Alzheimer disease\u2014a research prospectus. Nat Rev Neurol. 2021;17:689\u2013701.","journal-title":"Nat Rev Neurol"},{"key":"337_CR203","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/psyg.12218","volume":"17","author":"YS Kim","year":"2017","unstructured":"Kim YS, Lee KJ, Kim H. Serum tumour necrosis factor-\u03b1 and interleukin-6 levels in Alzheimer\u2019s disease and mild cognitive impairment. Psychogeriatrics. 2017;17:224\u201330.","journal-title":"Psychogeriatrics"},{"key":"337_CR204","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1093\/brain\/awx133","volume":"140","author":"MK Mamik","year":"2017","unstructured":"Mamik MK, Power C. Inflammasomes in neurological diseases: emerging pathogenic and therapeutic concepts. Brain. 2017;140:2273\u201385.","journal-title":"Brain"},{"key":"337_CR205","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018101064","volume":"38","author":"D Tejera","year":"2019","unstructured":"Tejera D, Mercan D, Sanchez-Caro JM, Hanan M, Greenberg D, Soreq H, et al. Systemic inflammation impairs microglial A\u03b2 clearance through NLRP3 inflammasome. EMBO J. 2019;38:e101064.","journal-title":"EMBO J"},{"key":"337_CR206","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","volume":"575","author":"C Ising","year":"2019","unstructured":"Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575:669\u201373.","journal-title":"Nature"},{"key":"337_CR207","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/brain\/awab337","volume":"144","author":"N Magusali","year":"2021","unstructured":"Magusali N, Graham AC, Piers TM, Panichnantakul P, Yaman U, Shoai M, et al. A genetic link between risk for Alzheimer\u2019s disease and severe COVID-19 outcomes via the OAS1 gene. Brain. 2021;144:3727\u201341.","journal-title":"Brain"},{"key":"337_CR208","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S1474-4422(20)30412-9","volume":"20","author":"A Serrano-Pozo","year":"2021","unstructured":"Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer\u2019s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021;20:68\u201380.","journal-title":"Lancet Neurol"},{"key":"337_CR209","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41392-022-01118-4","volume":"7","author":"H Zhang","year":"2022","unstructured":"Zhang H, Shao L, Lin Z, Long QX, Yuan H, Cai L, et al. APOE interacts with ACE2 inhibiting SARS-CoV-2 cellular entry and inflammation in COVID-19 patients. Signal Transduct Target Ther. 2022;7:261.","journal-title":"Signal Transduct Target Ther"},{"key":"337_CR210","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13195-021-00858-9","volume":"13","author":"N Xiong","year":"2021","unstructured":"Xiong N, Schiller MR, Li J, Chen X, Lin Z. Severe COVID-19 in Alzheimer\u2019s disease: APOE4\u2019s fault again? Alzheimers Res Ther. 2021;13:111.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"337_CR211","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2020.12.018","volume":"28","author":"C Wang","year":"2021","unstructured":"Wang C, Zhang M, Garcia G Jr, Tian E, Cui Q, Chen X, et al. ApoE-isoform-dependent SARS-CoV-2 neurotropism and cellular response. Cell Stem Cell. 2021;28:331\u201342.e5.","journal-title":"Cell Stem Cell"},{"key":"337_CR212","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.tins.2021.06.007","volume":"44","author":"A Guerrero","year":"2021","unstructured":"Guerrero A, De Strooper B, Arancibia-C\u00e1rcamo IL. Cellular senescence at the crossroads of inflammation and Alzheimer\u2019s disease. Trends Neurosci. 2021;44:714\u201327.","journal-title":"Trends Neurosci"},{"key":"337_CR213","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41583-020-0325-z","volume":"21","author":"S Saez-Atienzar","year":"2020","unstructured":"Saez-Atienzar S, Masliah E. Cellular senescence and Alzheimer disease: the egg and the chicken scenario. Nat Rev Neurosci. 2020;21:433\u201344.","journal-title":"Nat Rev Neurosci"},{"key":"337_CR214","first-page":"1775","volume":"323","author":"G Onder","year":"2020","unstructured":"Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323:1775\u20136.","journal-title":"JAMA"},{"key":"337_CR215","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41586-020-2918-0","volume":"590","author":"M O\u2019driscoll","year":"2021","unstructured":"O\u2019driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DT, Azman AS, Paireau J, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021;590:140\u20135.","journal-title":"Nature"},{"key":"337_CR216","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1474-4422(20)30231-3","volume":"19","author":"D Kellar","year":"2020","unstructured":"Kellar D, Craft S. Brain insulin resistance in Alzheimer\u2019s disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. 2020;19:758\u201366.","journal-title":"Lancet Neurol"},{"key":"337_CR217","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41577-019-0213-9","volume":"19","author":"MY Donath","year":"2019","unstructured":"Donath MY, Dinarello CA, Mandrup-Poulsen T. Targeting innate immune mediators in type 1 and type 2 diabetes. Nat Rev Immunol. 2019;19:734\u201346.","journal-title":"Nat Rev Immunol"},{"key":"337_CR218","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/1753-0407.13085","volume":"12","author":"A Rajpal","year":"2020","unstructured":"Rajpal A, Rahimi L, Ismail-Beigi F. Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. J Diabetes. 2020;12:895\u2013908.","journal-title":"J Diabetes"},{"key":"337_CR219","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.pcd.2021.04.004","volume":"15","author":"N Govender","year":"2021","unstructured":"Govender N, Khaliq OP, Moodley J, Naicker T. Insulin resistance in COVID-19 and diabetes. Prim Care Diabetes. 2021;15:629\u201334.","journal-title":"Prim Care Diabetes"},{"key":"337_CR220","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain. 2018;141:1917\u201333.","journal-title":"Brain"},{"key":"337_CR221","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s12035-020-02177-w","volume":"58","author":"MA Rahman","year":"2021","unstructured":"Rahman MA, Islam K, Rahman S, Alamin M. Neurobiochemical cross-talk between COVID-19 and Alzheimer\u2019s disease. Mol Neurobiol. 2021;58:1017\u201323.","journal-title":"Mol Neurobiol"},{"key":"337_CR222","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5802\/crbiol.8","volume":"343","author":"JP Changeux","year":"2020","unstructured":"Changeux JP, Amoura Z, Rey FA, Miyara M. A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. C R Biol. 2020;343:33\u20139.","journal-title":"C R Biol"},{"key":"337_CR223","doi-asserted-by":"publisher","first-page":"8226","DOI":"10.3390\/ijms22158226","volume":"22","author":"JT Hsu","year":"2021","unstructured":"Hsu JT, Tien CF, Yu GY, Shen S, Lee YH, Hsu PC, et al. The effects of A\u03b2(1\u201342) binding to the SARS-CoV-2 spike protein S1 subunit and angiotensin-converting enzyme 2. Int J Mol Sci. 2021;22:8226.","journal-title":"Int J Mol Sci."},{"issue":"4","key":"337_CR224","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3390\/ijms22041687","volume":"22","author":"Q Ding","year":"2021","unstructured":"Ding Q, Shults NV, Gychka SG, Harris BT, Suzuki YJ. Protein expression of angiotensin-converting enzyme 2 (ACE2) is upregulated in brains with Alzheimer\u2019s disease. Int J Mol Sci. 2021;22:1687.","journal-title":"Int J Mol Sci"}],"updated-by":[{"DOI":"10.1186\/s40035-023-00349-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000}}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-023-00337-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-023-00337-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-023-00337-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T07:12:37Z","timestamp":1728803557000},"score":1,"resource":{"primary":{"URL":"https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/s40035-023-00337-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":224,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["337"],"URL":"https:\/\/doi.org\/10.1186\/s40035-023-00337-1","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s40035-023-00349-x","asserted-by":"object"}]},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"assertion":[{"value":"29 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40035-023-00349-x","URL":"https:\/\/doi.org\/10.1186\/s40035-023-00349-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. The corresponding author SD. C. is the Editor-in-Chief of Translational Neurodegeneration. SD. C. did not participate in the peer review or decision-making of the review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}